Oncology

Responses to a cross-sectional survey brought to light disparities through important aspects of diagnosing and treating brain metastases.

Oncomine Dx Target Test is now approved by the FDA as a companion diagnostic for patients with IDH1-mutant cholangiocarcinoma who may be candidates for treatment with ivosidenib.

The VENTANA MMR RxDx Panel is the first FDA-approved companion diagnostic for identifying patients with DNA mismatch repair–deficient solid tumors who might benefit from treatment with dostarlimab-gxly.

Investigators theorize that a filgrastim-sndz biosimilar is an affordable option for patients across a number of tumor types who are undergoing curative intent treatment with chemotherapy and have an intermediate risk for experiencing febrile neutropenia.

A genomic-adjusted radiation dose model can aid in predicting radiotherapy benefit vs physical dose of radiotherapy pan-cancer.

Solid tumors with mismatch repair deficiency that have progressed on or after prior treatment and which have no suitable alternative therapy options may now be treated with dostarlimab following its approval by the FDA.

At a population level, those who were selected for surgery had a greater risk of dying from cancer related causes than dying from non-cancer causes.

The use of belzutifan has been approved by the FDA for patients with cancer that is associated with von Hippel-Lindau disease who do not need immediate surgery.

One in 3 popular cancer articles on social media contain potentially harmful misinformation, according to a report published in the Journal of the National Cancer Institute.

The makers of eflapegrastim received a complete response letter from the FDA due to concerns over manufacturing.

CancerNetwork® sat down with Funda Meric-Bernstam, MD, at the 2021 ASCO Annual Meeting to talk about results of the MyPathway study in HER2-positive advanced solid tumors treated with pertuzumab plus trastuzumab.

Oncologists are trying to remedy the proposed cuts to radiation oncology facilities from the Centers for Medicare and Medicaid Services to lessen health disparities and improve equitable access to care.

Here are some of the important updates from CancerNetwork last week you might have missed in the world of oncology, featuring novel combinations for triple-negative breast cancer, genetic testing for gastrointestinal malignancies, and the FDA approval of belumosudil for chronic graft-versus-host disease.

Take a look at some of the important updates from CancerNetwork last week you might have missed in the world of oncology from the FDA and the journal ONCOLOGY.

Profilin 1, or PFN1, is a key actin-binding protein that is involved in various cellular activities, such as cell motility, survival, and membrane trafficking. By summarizing the functions of PFN1 in cancer, investigators hope to better understand the mechanisms of PFN1 in cancer progression.

This year’s Annual Report to the Nation on the Status of Cancer highlights trends in cancer incidence and mortality overall and in key patient subgroups.

The FDA released a final guidance on evaluating cancer drugs in patients with central nervous system metastases.

CancerNetwork®’s podcast hosted 2 experts to discuss the current state of biosimilar prescriptions and the need for change to improve the system overall.

Catch up on the important updates from CancerNetwork® last week you might have missed in the world of oncology.

An integrated review highlights the barriers standing between diverse LGBTQ populations and cancer screenings.

Co-Editor in Chief of the journal ONCOLOGY discusses how potential shortages in oncology clinicians could influence the treatment of cancer going forward.

Here are some of the important updates from last week you might have missed, including data from the 2021 ASCO Annual Meeting.

Look at some of the important updates from last week you might have missed from the 2021 ASCO Annual Meeting and the FDA.

Look back at some of the important news and notes from last week you might have missed in the world of oncology from the 2021 ASCO Annual Meeting, the FDA, and the journal ONCOLOGY®.

Data from 2 clinical trials proved that larotrectinib is efficacious and safe in treating adults and children with NTRK fusion-positive central nervous system cancers.